<DOC>
	<DOCNO>NCT00156923</DOCNO>
	<brief_summary>This Phase 3 , multi-center extension Alkermes ' Study ALK21-003EXT ( NCT01218971 ) ass long-term safety repeat monthly dos Medisorb速 naltrexone ( VIVITROL速 ) .</brief_summary>
	<brief_title>ALK21-010 : Long-term Safety Medisorb速 Naltrexone ( VIVITROL速 ) Alcohol-dependent Adults</brief_title>
	<detailed_description>Enrolled subject continue receive dose strength Medisorb naltrexone ( ie , 190 mg 380 mg ) receive Study ALK21-003-EXT ( NCT01218971 ) . Assigned dose strength ( high low ) reveal subject , study investigator , blind member clinical study team duration study period . Placebo administer .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Primary Completed Study ALK21003EXT ( NCT01218971 ) , receive 13 injection Willing able return schedule clinic visit study assessment Noncustodial , stable address phone Written , inform consent Primary Pregnancy lactation Terminated early study drug Study ALK21003EXT ( NCT01218971 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Alcohol dependence</keyword>
</DOC>